# BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
Canonical URL: https://biopharmsignal.com/news/BCRX/biocryst-to-present-new-hae-data-from-orladeyor-berotralstat-and-navenibart-at-the-2026-european-academy-of-allergy-and-clinical-immunology-annual-meeting
Ticker: BCRX
Company: BioCryst Pharmaceuticals
Source: BioCryst Pharmaceuticals
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.biocryst.com
## Summary

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology

## Article Body
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio at the Annual Meeting of the European Academy of Allergy and Clinical Immunology
## Recent Company News
- 2026-07-02 11:00 EST — [BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/BCRX/biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-afb4cc8d) — Source: BioCryst Pharmaceuticals
- 2026-06-29 11:00 EST — [BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility](https://biopharmsignal.com/news/BCRX/biocryst-sharpens-scientific-focus-on-external-innovation-with-wind-down-of-inte-83b84c41) — Source: BioCryst Pharmaceuticals
- 2026-06-25 13:46 EST — [BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting](https://biopharmsignal.com/news/BCRX/biocryst-presents-new-clinical-data-and-real-world-evidence-demonstrating-impact-of-hae-portfolio-at-the-2026-european-academy-of-allergy-and-clinical-immunology-annual-meeting) — Source: BioCryst Pharmaceuticals
- 2026-06-25 13:46 EST — [BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting](https://biopharmsignal.com/news/BCRX/biocryst-to-present-new-hae-data-from-orladeyor-berotralstat-and-navenibart-at-the-2026-european-academy-of-allergy-and-clinical-immunology-annual-meeting) — Source: BioCryst Pharmaceuticals
- 2026-06-25 13:46 EST — [BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026](https://biopharmsignal.com/news/BCRX/biocryst-to-present-new-real-world-evidence-underscoring-the-ongoing-burden-of-pediatric-hereditary-angioedema-at-ispor-2026) — Source: BioCryst Pharmaceuticals
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)